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 Flavonoids, natural secondary
metabolites from plants, provide
many health benefits.
 Six flavonoids were synthesized in
yeast using glucose as sole carbon
source.
 Resokaempferol and fisetin were
synthesized in yeast for the first time.
 Flavonoids were synthesized via two
precursor-supplying routes.
 Quercetin and kaempferol had the
highest extracellular concentrations,
up to 20–26 mg L1.g r a p h i c a l a b s t r a c ta r t i c l e i n f o
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Saccharomyces cerevisiaea b s t r a c t
Yeast Saccharomyces cerevisiae was engineered for de novo production of six different flavonoids (narin-
genin, liquiritigenin, kaempferol, resokaempferol, quercetin, and fisetin) directly from glucose, without
supplementation of expensive intermediates. This required reconstruction of long biosynthetic pathways,
comprising up to eight heterologous genes from plants. The obtained titers of kaempferol
26.57 ± 2.66 mg L1 and quercetin 20.38 ± 2.57 mg L1 exceed the previously reported titers in yeast.
This is also the first report of de novo biosynthesis of resokaempferol and fisetin in yeast.
The work demonstrates the potential of flavonoid-producing yeast cell factories.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Flavonoids are aromatic secondary metabolites naturally
synthesized by plants and fungi from aromatic amino acids
L-phenylalanine and L-tyrosine. The structure of these phytochem-
icals is characterized by two phenolic rings and one heterocyclic
ring. The main differences between flavonoids are related to thehydroxylation patterns, the position of the second aromatic ring
and the saturation of the heterocyclic ring (Grotewold, 2006).
Bioactive polyphenols such as flavonoids play a fundamental role
in the physiology of plants; their natural functions include UV pro-
tection, reduction of oxidative damage in cells, and antibacterial
effect (Cushnie and Lamb 2011).
Research on human cells showed positive properties of
polyphenols in age-related diseases, cancer and cardiovascular dis-
eases (Woelfle et al., 2010; Bulzomi et al., 2012). Moreover, some
flavonoids, e.g., naringenin, have neuroprotective and antioxidant
properties. Liquiritigenin has been reported as a protective agent
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derivatives show antitumor and antidiabetic activity (Choi, 2012;
Wedick et al., 2012; Liu et al., 2012; Raza et al., 2013;
Hämäläinen et al., 2007). Kaempferol, quercetin and fisetin showed
anti-cancer, cardio-protective and anti-inflammatory effects (Chou
et al., 2013; Chen and Chen, 2013). Experiments with rats showed
that doses of 50 mg kg1 of quercetin inhibit the migration of mel-
anoma cells. Other experiments with humans showed that doses of
150 mg day1 of quercetin had positive effects on the health of
people with high risk of cardiovascular disease (Caltagirone et al.,
2000; Mukhtar et al., 2015). Fisetin has neuroprotective, neu-
rotrophic and anti-amyloid properties, which makes it a promising
therapeutic agent for neurodegenerative disorders such as Hunt-
ington and Alzheimer diseases (Maher et al., 2011; Currais et al.,
2014).
The main obstacles for large-scale production of flavonoids
from plant material are the long culture periods, requirements
for specific cultivation conditions and low abundance. Addition-
ally, extraction and purification processes add cost and result in
product loss and degradation (Wang et al., 2011; Routray and
Orsat, 2012). The concentration of flavonoids in different varieties
and sources of fruits oscillate between 30 and 4000 mg kg1 of dry
weight (Hertog et al., 1992; Paganga et al., 1999; Miean and
Mohamed, 2001; Crozier et al., 1997). This means that for the pro-
duction of 1 kg of flavonoids, it is required to process 0.25–33 Tons
of dry weight of fruits or vegetables.
Methods for phytochemicals extraction from agro-industrial
waste have been developed in the recent years, and secondary
metabolites such as carotenoids and flavonoids have been
extracted from this feedstock (Matharu et al., 2016; Pfaltzgraff
et al., 2013; Makris et al., 2007). Extraction of polyphenols such
as flavonoids from waste is promising, however there are chal-
lenges that have to be overcome in terms of cost and optimization
of extraction and purification methods (Mirabella et al., 2014;
Luthria, 2012).
For a sustainable supply of phytochemicals, it can be an advan-
tage to engage genetically engineered microbial cell factories, e.g.,
E. coli or S. cerevisiae. Koopman et al. (2012) reported production of
108.90 mg L1 of naringenin from glucose using an engineered
yeast strain. Furthermore, feeding naringenin to engineered cells
allowed production of other flavonoids, such as genistein, kaemp-
ferol and quercetin (Trantas et al., 2009). Production of naringenin
in E. coli reached 29 mg L1 using glucose as carbon source, while
kaempferol and quercetin have been produced using p-coumaric
acid as precursor and fisetin using L-tyrosine as a precursor
(Santos et al., 2011; Leonard et al., 2006; Stahlhut et al., 2015).
This study reports the development of a novel yeast cell factory
for de novo production of flavonoids from glucose. The target
flavonoids included: naringenin, liquiritigenin, kaempferol,
resokaempferol, quercetin, and fisetin. Intermediate compounds
and by-products were quantified to characterize regulated steps
in the pathways and to identify targets for future improvements
of the flavonoid-producing yeast cell factories.2. Methods
2.1. Plasmid construction
The plasmids with biosynthetic pathways for flavonoids pro-
duction were constructed using EasyClone 2.0 integrative plasmids
with auxotrophic and dominant selection markers (Stovicek et al.,
2015). The vectors integrate into well-defined integration sites
previously described by (Mikkelsen et al. 2012).
The genes used for flavonoids production were: 4-coumaroyl-
CoA ligase from Petroselinum crispum (4CL), chalcone synthase fromPetunia hybrida (CHS), chalcone reductase from Astragalus
mongholicus (CHR), chalcone isomerase from Medicago sativa
(CHI), flavanone 3-hydroxylase from Astragalus mongholicus (F3H),
flavonol synthase from Arabidopsis thaliana (FLS), cytochrome
P450 reductase from Catharanthus roseus (CPR), a cytochrome
P450 flavonoid monooxygenases from Fragaria ananassa and from
Petunia hybrida (FMO) (Fig. 1). All the genes were synthesized by
GeneArt (LifeTechnologies) in codon-optimized versions for E. coli
as stated in Stahlhut et al. (2015).
DNA fragments (BioBricks), encoding genes or promoters, were
amplified by PCR using primers and templates as described in
Table 1. Individual BioBricks were assembled into the integrative
plasmids by USER cloning as described previously (Stovicek et al.,
2015). Finally, the resulting vectors (Table 2) were verified by
sequencing.2.2. Strain construction
For expression of flavonoid biosynthetic pathways, in this
research were employed three S. cerevisiae strains, engineered to
produce p-coumaric acid (Table 3). The ST4757 strain was engi-
neered to produce p-coumaric acid using the phenylalanine
ammonia-lyase (PAL) pathway and the strains ST4069 and
ST2645 produced p-coumaric acid via the tyrosine ammonia-
lyase (TAL) pathway. To obtain flavonoid production, the strains
were transformed with NotI-linearized integrative vectors carrying
pathway genes via lithium acetate protocol (Gietz and Woods,
2002). The transformants were selected on synthetic drop-out
medium (Sigma-Aldrich), selecting for URA3, HIS5 and LEU2 mark-
ers. For selection on acetamide, the media contained 0.17 % yeast
nitrogen base without amino acids and ammonium sulfate and
6.6 g L1 of potassium sulfate and 0.6 g L1 acetamide. For selec-
tion of dominant markers NatMX, KanMX, BleMX or HphMX, the
medium was supplemented with 100 mg L1 nourseothricin,
200 mg L1 G418 disulfate salt, 10 mg L1 phleomycin or
200 mg L1 hygromycin B respectively. Correct integration of the
vectors was verified by yeast colony PCR. The yeast strains con-
structed in this study are listed in Table 3.2.3. Media and cultivations
For selection of yeast transformants and for routine cultivations,
synthetic complete (SC) medium as well as drop-out media (SC-
Ura, SC-Leu, SC-His) and agar plates were prepared using pre-
mixed drop-out powders from Sigma-Aldrich. Synthetic fed-batch
medium for S. cerevisiae M-Sc.syn-1000 (FIT) was purchased from
M2P Labs GmbH (Germany). The medium was supplemented with
vitamins solution (final 1% v/v) and the enzyme mix (final concen-
tration 0.5% v/v) immediately before use.
For the quantification of production of flavonoids for each
strain, five single colonies originating from independent transfor-
mants were tested. The colonies were inoculated in 0.5 ml drop-
out SC liquid medium without uracil, histidine, and/or leucine in
96-deep well microtiter plates with air-penetrable lid (EnzyScreen,
The Netherlands). The plates were incubated at 30 C with 250 rpm
agitation at 5 cm orbit cast overnight. 50 ml of the overnight cul-
tures were used to inoculate 0.5 ml synthetic fed-batch medium
in a 96-deep well plate. Fermentation was carried out for 72 h at
the same conditions as before. At the end of cultivation, samples
for metabolite analysis and optical density (OD) were taken.
OD600 was estimated as follows: 10 ml of fermentation broth was
mixed with 190 ml water in a 96 well microtiter plate and absor-
bance was measured at 600 nm wavelength in microplate reader
BioTek Synergy MX (BioTek). 200 ml of the culture were mixed with
200 ml of absolute ethanol, the mixture was centrifuged at 2272g
Fig. 1. Flavonoid biosynthetic pathways engineered into yeast S. cerevisiae. PAL2: phenylalanine ammonia-lyase; C4H: cinnamate 4-hydroxylyase; ATR2 cytochrome p450
reductase; CYB5: cytochrome b5 electron carrier; TAL: tyrosine ammonia-lyase; 4CL: 4-coumaroyl-CoA ligase; CHS: chalcone synthase; CHR: chalcone reductase; CHI:
chalcone isomerase; F3C: flavanone 3-hydroxylase; FLS: flavonol synthase; FMO: flavonoid 30-monooxygenase; CPR: cytochrome P450 reductase; alpha-KG: alpha-
ketoglutarate.
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Table 1
Primers used in this study and list of Biobricks generated by PCR amplification, description of the templates can be found in Stahlhut et al. (2015).
PRIMERS
USER cloning
ID Name Sequence (50-30)
7628 Pc_4Cl_U2_fw ATCTGTCAUAAAACAATGGGAGACTGTGTAGCAC
7629 Pc_4Cl_U2_rv CACGCGAUTCATTATTTGGGAAGATCACCGGATG
7632 Ph_CHS_U1_fw AGTGCAGGUAAAACAATGACCATGGTTACCGTTGAAG
7633 Ph_CHS_U1_rv CGTGCGAUTCATTAGGTTGCAACGCTATGCAG
7636 Ms_CHI_U1_fw AGTGCAGGUAAAACAATGACCATGGCAGCAAGC
7637 Ms_CHI_U1_rv CGTGCGAUTCATTAGTTGCCGATTTTAAAGGCACC
7640 Ms_CHR_U2_fw ATCTGTCAUAAAACAATGACCATGGGTAGCGTTG
7641 Ms_CHR_U2_rv CACGCGAUTCATTAGTCATCATACAGATCATTCAGACC
7644 At_F3H_U2_fw ATCTGTCAUAAAACAATGGCTCCAGGAACTTTGAC
7645 At_F3H_U2_rv CACGCGAUTCACTAAGCGAAGATTTGGTCGACAG
7648 At_FLS_U1_fw AGTGCAGGUAAAACAATGGAGGTCGAAAGAGTCC
7649 At_FLS_U1_rv CGTGCGAUTCATCAATCCAGAGGAAGTTTATTGAGC
7654 Fa_FMO-Cr_CPR_U1_fw AGTGCAGGUAAAACAATGGCGATTACCCTGCTG
7655 Fa_FMO-Cr_CPR_U1_rv CGTGCGAUTCATTACCAAACGTCACGCAGATAAC
7658 Ph_FMO-Cr_CPR_U1_fw AGTGCAGGUAAAACAATGGCGATTCTGTATACCGTG
7659 Ph_FMO-Cr_CPR_U1_rv CGTGCGAUTCATTACCAAACGTCACGCAGATAAC
Verification
ID Name Sequence (50-30)
892 Sc_XII-1-down-out-sq GGACGACAACTACGGAGGAT
894 Sc_XII-2-down-out-sq GGCCCTGATAAGGTTGTTG
900 Sc_XII-5-down-out-sq GTGGGAGTAAGGGATCCTGT
2220 Sc_Colo_pcr_fw CCTGCAGGACTAGTGCTGAG
8419 Sc_XI-5_down-out-sq GCATGGTCACCGCTATCAGC
BIOBRICKS
Name Template for PCR Fw primer for PCR Rv primer for PCR
BB0653 (Pc_4Cl?) pCDF-4cl-2Pc ID7628 (Pc_4Cl_U2_fw) ID7629 (Pc_4Cl_U2_rv),
BB0655(Ph_CHS ) pET-chsPh-chiMs ID7632 (Ph_CHS_U1_fw) ID7633 (Ph_CHS_U1_rv)
BB0656 (Ms_CHI ) pET-chsPh-chiMs ID7636 (Ms_CHI_U1_fw) ID7637 (Ms_CHI_U1_rv)
BB0658 (Am_CHR?) pRSF-chrAm ID7642 (Am_CHR_U2_fw) ID7643 (Am_CHR_U2_rv)
BB0659 (At_F3H?) pCDFf3hAt-fls-1At ID7644 (At_F3H_U2_fw) ID7645 (At_F3H_U2_rv)
BB0660 (At_FLS ) pCDFf3hAt-fls-1At ID7648 (At_FLS_U1_fw) ID7649 (At_FLS_U1_rv)
BB0661 (Fa_FMO-Cr_CPR ) pACYCf30hFxa2-cprCr ID7654 (Fa_F3H-Cr_CPR_U1_fw) ID7655 (Fa_F3H-Cr_CPR_U1_rv)
BB0680 (Ph_FMO-Cr_CPR ) pACYCf30hPh-cprCr ID7658 (Ph_F3H-Cr_CPR_U1_fw) ID7659 (Ph_F3H-Cr_CPR_U1_rv)
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Table 2
Plasmids used in this study.
Plasmid ID Genotype Source
Parental integrative plasmids
pCfB2399 pXI-5-lox P-amdSYMsyn, PTEF1-TADH1, PPGK1-TCYC1 Stovicek et al. (2015)
pCfB2197 pXII-1-lox P-NatMXsyn3, PTEF1-TADH1, PPGK1-TCYC1 Stovicek et al. (2015)
pCfB2225 pXII-2-lox P-KanMXsyn, PTEF1-TADH1, PPGK1-TCYC1 Stovicek et al. (2015)
pCfB2337 pXII-5-lox P-HPHMXsyn, PTEF1-TADH1, PPGK1-TCYC1 Stovicek et al. (2015)
pCfB2224 pXI-2-lox P-KanMXsyn, PTEF1-TADH1, PPGK1-TCYC1 Stovicek et al. (2015)
pCfB2855 pXII-2-lox P-amdSYM, PTEF1-TADH1, PPGK1-TCYC1 Stovicek et al. (2015)
Integrative plasmids for pathway expression
pCfB0848 pXI-2-loxP-URA3, PTEF1-CYB5 TADH1, PPGK1-ATR2-TCYC1 Li et al. (2016)
pCfB1018 pXI-5-loxP-HIS5, PTEF1-PAL2-TADH1, PPGK1-C4H TCYC1 Li et al. (2016)
pCfB3437 pXI-5-lox P-amdSYMsyn, PTEF1-Ph_CHS-TADH1, PPGK1-Pc_4CL-TCYC1 This study
pCfB2879 pXII-1-lox P-NatMXsyn3, PTEF1-Ms_CHI-TADH1, PPGK1-Am_CHR-TCYC1 This study
pCfB2893 pXII-1-lox P-NatMXsyn3, PTEF1-Ms_CHI-TADH1 This study
pCfB3643 pXII-2-lox P-KanMXsyn, PTEF1-At_FLS-TADH1, PPGK1-At_F3H-TCYC1 This study
pCfB3654 pXII-5-lox P-HPHMXsyn, PTEF1-Ph_FMO-Cr_CPR-TADH1 This study
pCfB3655 pXII-5-lox P-HPHMXsyn, PTEF1-Fa_FMO-Cr_CPR-TADH1 This study
pCfB4753 pXII-2-lox P-amdSYM, PTEF1-Ph_CHS-TADH1, PPGK1-Pc_4CL-TCYC1 This study
pCfB4754 pXI-2-lox P-KanMXsyn, PTEF1-At_FLS-TADH1, PPGK1-At_F3H-TCYC1 This study
pCfB4856 pXII-4-lox P-BleSyn, PTEF1-Ph_CHS-Am_CHR-TADH1 This study
pCfB4857 pXII-4-lox P-BleSyn, PTEF1-Ph_CHS-TADH1, PPGK1-Am_CHR-TCYC1 This study
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concentration by HPLC.
2.4. Quantification and identification of flavonoids
Quantification of flavonoids was performed on a Dionex Ulti-
mate 3000 HPLC equipped with a Discovery HS F5
150 mm  4.6 mm column (particle size 5 mm) connected to a UV
detector (277, 290, 333 and 370 nm). Samples were analyzed using
a gradient method with two solvents: 10 mM ammonium formate
pH 3.0 (A) and acetonitrile (B). For p-coumaric acid, naringenin and
liquiritigenin detection, a flow rate of 1.5 ml min1 was used. The
program started with 5% of solvent B (0–0.5 min), after which its
fraction was increased linearly from 5% to 60% (0.5–7 min), then
the fraction was maintained at 60% (7–9.5 min), after that the frac-
tion was decreased from 60% to 5% (9.5–9.6 min), finally, the frac-
tion was maintained at 5% (9.6–12 min). p-Coumaric acid was
detected at 5.6 min (333), liquiritigenin at 6.8 (277) and naringenin
at 7.5 min (290 nm). For kaempferol, resokaempferol, quercetin
and fisetin detection, a flow rate of 1.5 ml min1 was used. The
program started with 20% of solvent B (0–2 min), after which its
fraction was increased linearly from 20% to 45% (2–20 min), then
the fraction was decreased from 45% to 20% (20–22 min) and main-
tained at 20% for 2 min (22–24 min). Fisetin was detected at
10.3 min (333 nm), liquiritigenin at 12.8 min (277 nm), reso-
kaempferol at 13.3 min (370 nm) and quercetin at 13.9 min
(370 nm).
The pure compounds p-coumaric acid (98.0%), naringenin
(98%), kaempferol (97.0%), quercetin (97.0%) and fisetin
(98.0%) were purchased from Sigma Aldrich Co. (Denmark);
liquiritigenin (98.0%) was purchased from Tocris Bioscience (Uni-
ted Kingdom) and resokaempferol (95.0%) was purchased from
Extrasynthese (France). The compounds were used to generate cal-
ibration curves; the areas were integrated with Chromeleon 7 and
used for quantification. The flavonoids were identified by compar-
ing the retention times and UV absorbance spectra of the samples
with authentic compounds. For all the strains five biological repli-
cates were analyzed.
2.5. Identification of fisetin
For fisetin identification, the samples were dried at room tem-
perature under reduced pressure using a Centrifugal Vacuum Con-centrator (Savant Speed Vacs Concentrator, Thermofisher
Scientific, Waltham Ma), followed by reconstitution using a 0.1%
solution of formic acid in LC-MS grade acetonitrile. 20 ml of each
sample were then injected and analyzed on a Dionex UltiMate
3000 UHPLC (Thermo Fisher Scientific, San Jose, CA) connected to
an Orbitrap Fusion Mass Spectrometer (Thermo Fisher Scientific,
San Jose, CA). The UHPLC used a Supelco Discovery HS F5-3,
15 cm  2.1 mm, 3 lm column. Temperature was 30 C and flow
rate was 0.6 mL/min with a mobile phase of 95% 0.1 % formic acid
(mobile phase A) and 5% acetonitrile with 0.1% formic acid (mobile
phase B) for 2 min followed by a linear gradient to 95% mobile
phase B over 12 min. This gradient was held for 2 min after which
it was changed immediately to 95% mobile phase A and 5% mobile
phase B and held for 6 min. The sample was passed on to the MS
equipped with a heated electrospray ionization source (HESI) in a
positive-ion mode with nitrogen as nebulizer gas (52 a.u.). The
cone and probe temperatures were 356 C and 420 C, respectively.
Probe gas flow was 16 a.u. and spray voltage was 3500 V. Scan
range was 150–1000 Da and time between scans was 100 ms.3. Results and discussion
3.1. Flavonoids pathway design
Previously, Stahlhut et al. reported reconstruction of a biosyn-
thetic pathway for the production of fisetin from L-tyrosine in
E. coli (Fig. 1) (Stahlhut et al., 2015). This study aimed to develop
a fermentation process for de novo production of a portfolio of
related flavonoids from a cheap carbon source and using yeast S.
cerevisiae as the host. The biosynthetic pathway towards flavo-
noids is depicted in Fig. 1. The precursor, p-coumaric acid, was syn-
thesized either from L-tyrosine via tyrosine ammonia-lyase (TAL)
or from L-phenylalanine by the use of phenylalanine ammonia-
lyase (PAL). First, p-coumaric acid must be activated by a 4-
coumaroyl-CoA ligase 4CL, and for this a variant from P. crispum
was used. Next, chalcone synthase CHS from P. hybrida and chal-
cone isomerase CHI fromM. sativa were used to convert the result-
ing p-coumaroyl-CoA and three molecules of malonyl-CoA into
naringenin. To obtain isoliquiritigenin, chalcone reductase CHR
from A. mongholicus was additionally overexpressed. The resulting
naringenin and isoliquiritigenin producing strains were further
engineered towards production of respectively kaempferol and
resokaempferol by overexpression of flavanone 3-hydroxylase
Table 3
Strains used in this study.
Platform strains producing p-coumaric acid
Strain ID Genotype Source
ST4069 Mata PTEF1? Fj_TAL Rodriguez et al. (2015)
ST2645 Mata PTEF1? Fj_TAL, PTEF1? Sc_ARO7G141s, PPGK1? Sc_ARO4K229L, Daro10 Dpdc5 Rodriguez et al. (2015)
ST4757 Mata PTEF1? PAL2, PPGK1? C4H, PPGK1? CYB5, PTEF1? ATR2 This study
Strains transformed with integrative plasmids
Strain ID Parent strain Integrated plasmids Integrated flavonoid pathway genes Source
ST5066 ST4069 pCfB3437, pCfB2893 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI This study
ST5067 ST4069 PCFB343, pCfB2879 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? CHR This study
ST5068 ST2645 PCfB3437, pCfB2893 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI This study
ST5069 ST2645 PCfB3437, pCfB2879 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? CHR This study
ST5070 ST5068 pCfB3643 PPGK1? 4CL, PPGK1? CHS, PTEF1? CHI, PPGK1? F3H, PTEF1? FLS This study
ST5071 ST5069 pCfB3643 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? F3H, PTEF1? FLS This study
ST5072 ST5070 pCfB3654 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? F3H, PTEF1? FLS,
PTEF1? Fa_FMO CPR
This study
ST5073 ST5070 pCfB3655 PTEF1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? F3H, PTEF1? FLS,
PTEF1? Ph_FMO-CPR
This study
ST5074 ST5071 pCfB3654 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? CHR, PPGK1? F3H,
PTEF1? FLS, PTEF1? Fa_FMO-CPR
This study
ST5075 ST5071 pCfB3655 PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? CHR, PPGK1? F3H,
PTEF1? FLS, PTEF1? Ph_FMO-CPR
This study
ST4972 ST4757 PCfB4753, PCfB4754,
PCfB2879, PCfB3654
PPGK1? 4CL, PTEF1? CHS, PTEF1? CHI, PPGK1? CHR, PPGK1? F3H,
PTEF1? FLS, PTEF1? Ph_FMO-CPR
This study
ST5401 ST5074 pCfB4856 PTEF1? CHS-CHR (fusion) This study
ST5402 ST5074 pCfB4587 PTEF1? CHS, PPGK1? CHR This study
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Lastly, two different cytochrome P450 flavonoid monooxygenases
FMOs, one from F. ananassa and another from P. hybrida, were over-
expressed in the kaempferol-producing strain to obtain quercetin
and in the resokaempferol-producing strain to obtain fisetin. Each
of the tested FMOs was fused in-frame with cytochrome P450
reductase CPR from C. roseus.
3.2. Biosynthesis of naringenin and liquiritigenin
To begin with, two platform strains, producing low or high
amounts of p-coumaric acid, were explored for their capacity to
make naringenin and liquiritigenin. Strain ST4069, which produced
0.24 ± 0.03 g L1 of p-coumaric acid in the previous study, was
employed as the low-producer, while strain ST2645, which reached
a titer of 1.93 ± 0.26 g L1, was used as the high-producer
(Rodriguez et al., 2015). Strain ST4069 has overexpression of a
TAL gene, while strain ST2645 has additional modifications increas-
ing the flux towards aromatic amino acids: knock-outs of ARO10
and PDC5 genes and over-expressions of ARO4fbr and ARO7fbr. To
obtain naringenin production, 4-coumaroyl-CoA ligase 4CL, chal-
cone synthase CHS and chalcone isomerase CHI were overex-
pressed. For liquiritigenin production, chalcone reductase CHR
was additionally overexpressed. The titers of naringenin and liquir-
itigenin were ca. 3-fold higher in the strain background with opti-
mized p-coumaric acid production, reaching 1.55 ± 0.13 mg L1 of
naringenin and 5.31 ± 0.48 mg L1 of liquiritigenin. p-Coumaric
acid accumulated in the medium, particularly in the optimized
strains, where up to 8 mg L1 of p-coumaric acid were measured.
Naringenin (1 mg L1) also accumulated alongside liquiritigenin,
indicating incomplete reduction by CHR (Fig. 2A–D).
3.3. Biosynthesis of kaempferol and resokaempferol
The naringenin- (strain ST5068) and liquiritigenin- (strain
ST5069) producing strains were further engineered for production
of respectively kaempferol and resokaempferol by overexpressing
the genes encoding flavanone 3-hydroxylase F3H and flavonol syn-
thase FLS. As a result, two new strains were obtained, strain ST5070
for the production of kaempferol and strain ST5071 for theproduction of resokaempferol. Strain ST5070 produced 26.57 ±
2.66 mg L1 of kaempferol as well as two pathway intermediates:
10.75 ± 0.87 mg L1 of p-coumaric acid and 0.83 ± 0.05 of narin-
genin (Fig. 2E). The high titer of kaempferol was surprising, consid-
ering that the parent strain produced less than 2 mg L1 of
kaempferol precursor, naringenin. The depletion of naringenin
and higher capacity to produce kaempferol imply that the conver-
sion steps of naringenin into kaempferol are very efficient. The
resokaempferol producing strain (ST5071) accumulated 0.51 ±
0.03 mg L1 of resokaempferol, 14.54 ± 1.96 mg L1 of p-coumaric
acid, 11.39 ± 0.33 mg L1 of kaempferol, and less than 1 mg L1 of
naringenin and liquiritigenin (Fig. 2F). In the resokaempferol
strain, by-product kaempferol was produced, which results from
incomplete reduction of p-coumaroyl-CoA by CHR.
3.4. Biosynthesis of fisetin and quercetin
For the production of quercetin and fisetin, it is necessary to
overexpress cytochrome P450 flavonoid monooxygenase (FMO)
and cytochrome P450 reductase (CPR). In this study, two FMO vari-
ants were evaluated, one from F. ananassa and another from P.
hybrida. Each FMO was fused in-frame to the CPR from C. roseus
by a flexible glycine-serine linker (50-GGGTCGAC-30).
The genes were overexpressed in the kaempferol producing
strain (ST5068) to obtain 16.04 ± 0.37 mg L1 and
20.38 ± 2.57 mg L1 of quercetin in the strains with FMO from F.
ananassa and P. hybrida respectively (Fig. 2G and I). For fisetin
biosynthesis, the host strain was the strain engineered for reso-
kaempferol production (ST5069). Upon overexpression of FMO-
CPR fusions, 1.20 ± 0.19 mg L1 and 1.65 ± 0.10 mg L1 of fisetin
was obtained respectively (Fig. 2H and J). The strains overexpress-
ing the FMO of F. ananassa additionally accumulated kaempferol
and naringenin, while the strains with FMO from P. hybrida did
not secrete these intermediates, hence the latter strain (ST5074)
was chosen for further work. Fisetin was detected when expressing
both the FMO from F. ananassa and P. hybrida. The observed ion 287
in positive mode is congruent with the ions recognized in the fise-
tin standard. The spectra for the infusion of the fisetin standard
gave an ion with m/z 287.0549, which corresponds to 0.35 ppm
of ion with the ionic formula of C15H11O6 in positive ion mode;
Fig. 2. Strains engineered for biosynthesis of flavonoids via TAL pathway. A. Naringenin pathway expressed in low-level p-CA strain ST4069. B. Liquiritigenin pathway
expressed in low-level p-CA strain ST4069. C. Naringenin pathway expressed in high-level p-CA strain ST2645. D. Liquiritigenin pathway expressed in high-level p-CA strain
ST2645. E. Kaempferol pathway expressed in high-level p-CA strain ST2645. F. Resokaempferol pathway expressed in high-level p-CA strain ST2645. G. Quercetin pathway
expressed in high-level p-CA strain ST2645; flavonoid 30-monooxygenase (FMO) from F. ananassa. H. Fisetin pathway expressed in high-level p-CA strain ST2645; flavonoid 30-
monooxygenase (FMO) from F. ananassa. I. Quercetin pathway expressed in high-level p-CA strain ST2645; flavonoid 30-monooxygenase (FMO) from P. hybrida. J. Fisetin
pathway expressed in high-level p-CA strain ST2645; flavonoid 30-monooxygenase (FMO) from P. hybrida. The strains were cultivated in FIT medium for 72 h, the mean value
of extracellular concentration of compounds was calculated from five biological replicates.
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Fig. 3. Strains engineered for the optimized biosynthesis of fisetin. A. ST5401,
fisetin producer strain (ST5075) with an additional copy of fused CHS and CHR B.
ST5402, fisetin producer strain (ST5075) with an additional copy of CHS and CHR. C.
Strain ST4972 engineered for biosynthesis of fisetin using the PAL pathway. The
background strain for strains ST5401 and ST5402 was strain ST5074. The strains
were cultivated in FIT medium for 72 h, the mean value of extracellular concen-
tration of compounds was calculated from five biological replicates.
1652 A. Rodriguez et al. / Bioresource Technology 245 (2017) 1645–1654this is indicative of a compound with a molecular formula of
C15H10O6.
3.5. Improving fisetin production via heterologous pathway
optimization
The strains designed to produce fisetin, accumulated significant
amounts of quercetin. It was hypothesized that more flux could be
re-directed into fisetin by exploiting the metabolic channeling
effect, which had proven effective in other studies (Albertsen
et al., 2011; Stahlhut et al., 2015). A fusion of CHS and CHR proteins
was overexpressed in the fisetin-producing strain ST5074, result-
ing in ST5401. A control strain, ST5402, expressing an additional
copy of non-fused CHS and CHR was constructed as well. Both
strains produced higher titer of fisetin than the parental strain:
strain ST5401 produced 2.11 ± 0.26 mg L1 and strain ST5402 pro-
duced 2.29 ± 0.07 mg L1 in comparison to 1.65 ± 0.01 mg L1 for
the parental strain ST5074 (Fig. 3A and B). As the competing by-
product, quercetin, accumulated to the same concentration as in
the strain without additional copies of CHS and CHR, the ratio of
the product (fisetin) to by-product (quercetin) was slightly
improved. However, the fusion clearly did not provide an addi-
tional advantage in comparison to overexpression of separate
enzymes, and further work is needed to optimize the linkage
between the two proteins.
The strains engineered for liquiritigenin, resokaempferol and
fisetin production accumulated significant amounts of by-
products. Particularly obtaining the products in the reduced branch
was difficult and was always accompanied by production of non-
reduced analogues. By overexpressing an extra copy of chalcone
synthase CHS and chalcone reductase CHR, fisetin titer was
increased from 1.65 ± 0.10 mg L1 to 2.29 ± 0.07 mg L1. Clearly,
further improvement of chalcone reductase is needed to obtain
the reduced flavonoids.
When assembling novel heterologous pathways for production
of the complex metabolites, it is important to engineer (or isolate)
a microbial host with a sufficient pool of precursor metabolites for
a given product and to ensure balanced enzymatic activities of the
multistep metabolic pathways in order to avoid accumulation of
intermediates and by-products (Venugopalan et al., 2016; Badle
et al., 2014). Therefore, several engineered platform strains with
different production capacities for production of flavonoids precur-
sor p-coumaric acid were tested. In all cases, when the strains with
improved flux towards p-coumaric acid via TAL route were imple-
mented, an improvement in production of the downstream flavo-
noids was observed.
The accumulation of p-coumaric acid was common for all the
engineered strains. The accumulation of this precursor indicates
a limiting step for the conversion of p-coumaric acid into p-
coumaroyl-CoA. Previous research reported the same limiting step
in E. coli and yeast; they associated the accumulation of p-coumaric
acid to the lack of malonyl-CoA or low activity of the 4CL for con-
version of p-coumaric acid into p-coumaroyl-CoA (Stahlhut et al.,
2015; Koopman et al., 2012). To overcome this limitation, other
natural or engineered variants of 4CL can be tested and the supply
of malonyl-CoA can be improved (Shi et al., 2014). Another
possibility for improvements could be testing several different
S. cerevisiae strain backgrounds, as miniature genetic and
phenotypic differences might result in significant differences of
the final yields of phytochemicals and biofuels (Strucko et al.,
2015; Pereira et al., 2014). In higher plants, flavonoid biosynthetic
enzymes are co-localized and assembled in protein complexes
and the metabolic channeling effect decreases formation of
by-products. In analogy, compartmentalizing or scaffolding the
flavonoid biosynthetic enzymes in yeast may have a positive effect
on the enzymatic activity and therefore on flavonoids production(Jeon et al., 2015; Avalos et al., 2013; Woolston et al., 2013;
Dueber et al., 2009). Further studies are needed on kinetic regula-
tion of the flux through the flavonoids pathway, on the degradation
and secretion of flavonoids.
3.6. Biosynthesis of flavonoid via phenylalanine
Several studies have previously demonstrated that p-coumaric
acid, the first intermediate of de novo flavonoid pathway, can be
synthesized in S. cerevisiae via two routes: through tyrosine
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(Koopman et al., 2012; Li et al., 2015). In this study, the capacity
of TAL and PAL routes to supply metabolic precursors for flavonoid
production was compared. For this, a strain producing p-coumaric
acid via PAL route was constructed (ST4757). The strain featured
overexpression of CYB5 from S. cerevisiae and PAL2, ATR2 and C4H
and from Arabidopsis thaliana. The pathway for biosynthesis of fise-
tin was introduced into this strain as the next step. The pathway
was analogous to the one described above in ST5074. Interestingly,
HPLC analysis of the resulting final PAL-based strain (ST4972)
revealed a different metabolic profile (Fig. 3C) as compared to the
corresponding TAL-based strain. More specifically, a 5.7-fold
higher accumulation of p-coumaric acid (70 mg L1) was observed,
while fisetin was only found in trace amounts and could not be
quantified.
Surprisingly, when PAL route was applied for the production of
fisetin, a much higher accumulation of p-coumaric acid was
observed (69.07 ± 17.81 mg L1 instead of 12.63 ± 0.76 mg L1),
the production of quercetin was lower and there was no produc-
tion of fisetin. Another surprising discovery was the relatively high
titer of kaempferol (26.57 ± 2.66 mg L1), despite the parental
strain produced only 1.55 ± 0.13 mg L1 of kaempferol precursor,
naringenin. This phenomenon could be explained by intracellular
degradation of naringenin, its instability in the medium or lower
secretion of kaempferol (Mora-Pale et al., 2013; Du et al., 2010).4. Conclusions
This work presents a proof-of-concept biosynthesis of flavo-
noids in engineered yeast cell factories. An array of yeast strains
expressing heterologous flavonoid metabolic pathways was suc-
cessfully developed. The strains contained up to eight genes, where
some of the strains produced significant flavonoid titers in double-
digit mg L1 range. Moreover, the study demonstrated that flavo-
noids can be synthesized via two different precursor-supplying
routes, via tyrosine ammonia-lyase or phenylalanine ammonia-
lyase. The compounds quercetin and kaempferol were the ones
with the highest extracellular concentrations detected in this
study. This study is the first report on the biosynthesis of reso-
kaempferol and fisetin in yeast.
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